STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #779 by analyst upside · 2026-06-27
EVMN
Evommune, Inc.
Healthcare · Market Cap $907M · P/E 0x
ANALYST PRICE TARGET
+107.5%
implied upside to consensus target
Current Price $25.18
Consensus Target $52.25
Bull Target $55.0
Bear Target $50.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
0
Sell
0
52-Week Low $13.88
52-Week High $33.2
YTD Return +45.5%
FUNDAMENTALS
Market Cap $907M
P/E Ratio (TTM) N/A
Forward P/E -7.8x
EPS (TTM) $-2.20
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $13.88
52-Week High $33.2
Current Price $25.18
Bear Target $50.0
Bull Target $55.0
● Now $25.18 ● Target $52.25
TRADING DATA
Avg Volume 396K
YTD Return +45.5%
Analyst Count 8
Consensus Buy
Upside to Target +107.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Evommune, Inc. (EVMN) is currently trading at $25.18 with a Wall Street consensus price target of $52.25, implying potential upside of 107.5% over the next 12 months. 8 analysts currently cover EVMN, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $55.0, while the most cautious has a target of $50.0.

EVMN operates in the Healthcare sector with a market capitalisation of $907M. The stock is up 45.5% year-to-date and is currently trading near the upper end of its 52-week range of $13.88 – $33.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for EVMN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-26 31% win rate (48 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-05-11 Building track record
RBC Capital reit
Outperform → Outperform 2026-04-10 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-18 31% win rate (48 calls)
Clear Street ● Initiated
Buy 2026-03-18 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-02-10 31% win rate (48 calls)
Oppenheimer ● Initiated
Outperform 2026-01-22 14% win rate (7 calls)
Raymond James ● Initiated
Strong Buy 2026-01-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
70
out of 100
Coverage depth
17/30
Consensus clarity
26/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →